Aeglea BioTherapeutics Secures $12,000,000 New Funding

  • Feed Type
  • Date
    1/9/2014
  • Company Name
    Aeglea BioTherapeutics
  • Mailing Address
    815-A Brazos St. Austin, TX 78701
  • Company Description
    Aeglea BioTherapeutics is a Texas based start up developing two drugs invented at UT Austin, novel engineered human enzymes that degrade the amino acids L-methionine (L-Met), or L- arginine (LArg) in the circulation. These drugs target the dependence of different tumors on L- Met or L-Arg for survival.
  • Website
    Undisclosed
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $12,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    During the next 15 to 18 months, the company plans to begin manufacturing of its lead molecule and complete the prep work to begin the first phase of clinical trials.
  • M&A Terms
  • Venture Investor
    KBI Biopharma

Trending on Xconomy